Qiagen NV
NYSE:QGEN

Watchlist Manager
Qiagen NV Logo
Qiagen NV
NYSE:QGEN
Watchlist
Price: 43.24 USD -0.02%
Market Cap: 9.6B USD
Have any thoughts about
Qiagen NV?
Write Note

Gross Margin
Qiagen NV

62.7%
Current
64%
Average
43.8%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
62.7%
=
Gross Profit
1.2B
/
Revenue
2B

Gross Margin Across Competitors

Country NL
Market Cap 9.6B USD
Gross Margin
63%
Country US
Market Cap 1.3T USD
Gross Margin
55%
Country US
Market Cap 196.2B USD
Gross Margin
41%
Country US
Market Cap 170.9B USD
Gross Margin
60%
Country KR
Market Cap 67.8T KRW
Gross Margin
49%
Country CH
Market Cap 38.5B CHF
Gross Margin
29%
Country US
Market Cap 38.6B USD
Gross Margin
55%
Country US
Market Cap 36.5B USD
Gross Margin
35%
Country US
Market Cap 26.7B USD
Gross Margin
59%
Country US
Market Cap 23.2B USD
Gross Margin
35%
Country US
Market Cap 23B USD
Gross Margin
60%
No Stocks Found

Qiagen NV
Glance View

Market Cap
9.6B USD
Industry
Life Sciences Tools & Services

Qiagen NV is a leading global provider of sample and assay technologies that empower researchers and healthcare professionals in their quest for answers in genomics and molecular biology. Founded in 1984 and headquartered in Hilden, Germany, the company has established a formidable presence in the biotechnology sector, offering innovative solutions that facilitate the detection of diseases, genetic research, and drug development. Qiagen’s diverse portfolio spans from nucleic acid extraction kits to molecular diagnostic tests, catering to both academic research institutions and clinical settings. This extensive product range not only supports the growing demand for precision medicine but also aligns with global health trends emphasizing personalized treatments based on genetic insights. For investors, Qiagen presents an appealing opportunity as it operates in a lucrative market characterized by robust growth prospects. The company has consistently demonstrated its ability to adapt to changing healthcare landscapes, evidenced by its strategic focus on expanding offerings in molecular diagnostics and companion diagnostics, which underpin the future of targeted therapies. Additionally, Qiagen's commitment to innovation is underscored by significant investments in research and development, positioning it well to capitalize on advances in the rapidly evolving life sciences market. With a strong financial track record and a commitment to enhancing shareholder value through strategic partnerships and acquisitions, Qiagen is not just a participant in the biotech ecosystem; it is a leader steering the course for future advancements in health and research.

QGEN Intrinsic Value
41.23 USD
Overvaluation 5%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
62.7%
=
Gross Profit
1.2B
/
Revenue
2B
What is the Gross Margin of Qiagen NV?

Based on Qiagen NV's most recent financial statements, the company has Gross Margin of 62.7%.